Trials / Recruiting
RecruitingNCT07108270
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dostarlimab | Dostarlimab will be administered. |
| DRUG | Carboplatin | Carboplatin will be administered. |
| DRUG | Paclitaxel | Paclitaxel will be administered. |
Timeline
- Start date
- 2025-11-27
- Primary completion
- 2030-03-31
- Completion
- 2030-03-31
- First posted
- 2025-08-07
- Last updated
- 2025-12-22
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07108270. Inclusion in this directory is not an endorsement.